Shukra Pharmaceuticals (BOM:524632) Moat Score: 0/10 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524632 Shukra Pharmaceuticals Ltd BOM:524632
72 GF Score
Price ₹31.72
GF Value ₹8.64
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Moat Score?

Shukra Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Shukra Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Shukra Pharmaceuticals might have No Moat - No discernible moat.

Shukra Pharmaceuticals  (BOM:524632) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Shukra Pharmaceuticals Moat Score Related Terms

BOM:524632
72GF Score
Shukra Pharmaceuticals Ltd BOM:524632
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹31.72 is trading 267.1% above its estimated GF Value™ of ₹8.64. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524632:

  • Moat Score: 0
  • GF Value™: ₹8.64 vs. price of ₹31.72 (267.1% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
72GF Score

Get the complete analysis for BOM:524632

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.72
Price
₹8.64
GF Value